Canaccord Genuity Increases Vapotherm (VAPO) Price Target to $27.00

Vapotherm (NYSE:VAPO) had its price target boosted by equities researchers at Canaccord Genuity from $22.00 to $27.00 in a report released on Wednesday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s target price points to a potential upside of 35.00% from the stock’s current price.

A number of other equities analysts have also recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Vapotherm in a research note on Monday, December 10th. Bank of America began coverage on shares of Vapotherm in a research note on Monday, December 10th. They set a “buy” rating and a $26.00 price target for the company. Finally, BTIG Research began coverage on shares of Vapotherm in a research note on Monday, December 10th. They set a “buy” rating for the company.

Shares of NYSE:VAPO opened at $20.00 on Wednesday. Vapotherm has a 52 week low of $14.70 and a 52 week high of $22.07. The firm has a market capitalization of $332.13 million and a price-to-earnings ratio of -1.45.



Vapotherm (NYSE:VAPO) last issued its quarterly earnings data on Tuesday, March 12th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.12. The business had revenue of $11.69 million during the quarter, compared to analysts’ expectations of $11.00 million. As a group, sell-side analysts anticipate that Vapotherm will post -2.7 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. purchased a new stake in Vapotherm in the 4th quarter valued at about $61,000. New York State Common Retirement Fund purchased a new stake in Vapotherm in the 4th quarter valued at about $118,000. Barclays PLC purchased a new stake in Vapotherm in the 4th quarter valued at about $142,000. Arnhold LLC purchased a new stake in Vapotherm in the 4th quarter valued at about $227,000. Finally, Bank of New York Mellon Corp purchased a new stake in Vapotherm in the 4th quarter valued at about $346,000. 47.51% of the stock is owned by institutional investors.

Vapotherm Company Profile

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Read More: How to invest in a bear market

The Fly

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.